One injection. One hundred thousand dollars. No other option.
On August 16, 2026, 59-year-old Josh from New Zealand hugged his doctor and walked out of Shanghai Jiahui International Hospital. He had just finished a month and a half of cancer treatment. Ahead of him: an 11-hour flight home.
Josh became the world's first foreign patient to receive CAR-T cell therapy for a solid tumor in China. Months earlier, doctors in New Zealand had told him his cancer treatment had failed. He was too weak to eat, kept alive by tube feeding. He spent weeks searching the internet for the newest cancer treatments. He found one — but only one country offered it.
China.
What is CAR-T therapy — and why the solid-tumor version matters
CAR-T (chimeric antigen receptor T-cell) therapy is a personalized cancer treatment. Doctors collect your own immune cells, genetically engineer them to recognize and attack cancer cells, then infuse them back into your body. These "living drugs" keep fighting cancer for months or years.
For years, CAR-T worked well on blood cancers like leukemia and lymphoma, but failed on solid tumors. Solid tumors hide from immune cells and build a hostile environment around themselves. Until recently, no CAR-T product anywhere in the world had been approved for solid tumors.
Then, in June 2026, China's National Medical Products Administration (NMPA) approved the world's first CAR-T therapy for solid tumors — a product called satri-cel (by CARsgen), designed for gastric and other solid tumors. The same month, another China-only drug, ivonescimab, was approved for first-line treatment of squamous non-small-cell lung cancer.
Here's the key point for patients: some of the world's most advanced cancer treatments are currently only available in China. Not the US. Not Europe. China.
The cost: 99万 RMB (about $140,000) — and why patients still come
The price tag for a single CAR-T injection is 999,000 RMB (about $140,000 USD). Even in New Zealand, where the average annual salary is about 356,000 NZD (roughly $210,000), that's a serious amount of money.
But here's what patients who have run out of options understand: it's not about the absolute price. It's about what's available.
For blood-cancer CAR-T, China's price is roughly one-third of the US price. In the US, a CAR-T treatment can run $400,000–$500,000 for the drug itself, before hospital costs. In China, the same category of therapy costs a fraction of that.
| Treatment | China cost | US cost |
|---|---|---|
| CAR-T (blood cancer) | ~$45,000–70,000 | ~$400,000–500,000 |
| CAR-T (solid tumor, satri-cel) | ~$140,000 (world's first) | Not available |
| Ivonescimab (lung cancer) | ~$20,000–30,000/yr | Not approved in US |
| PET-CT scan | ~$150–300 | ~$1,000–3,000 |
The story of Daniel, an American patient, shows why. Daniel had tried four different treatments in the US. His doctors at MD Anderson told him there was nothing left to try — except one drug that might be his last hope. That drug, ivonescimab, was only approved in China. Daniel's children, both doctors, arranged for him to fly to Shanghai in March 2026 for treatment.
What actually happens during treatment in China
Treatment at Shanghai Jiahui International Hospital — the hospital serving the most foreign patients in Shanghai, with over 100,000 foreign patient visits in 2025 — is built around speed and coordination.
- 48-hour diagnostics: Bone marrow biopsy, lab tests, PET-CT, cardiac ultrasound, and lung function tests all come back within 48 hours, with doctor consultations arranged immediately.
- Fast time-to-treatment: In China, the average time from first diagnosis to surgery is weeks. In the US and Europe, patients often wait months just for appointments and insurance pre-approval.
- Multidisciplinary teams: When Daniel developed a severe immune-related adverse reaction, Jiahui organized multiple rounds of internal and external expert consultations, including the lead investigator of the drug, Professor Zhou Caicun from Tongji University-affiliated East Hospital.
- Multilingual care: Jiahui provides services in 8 languages and medical documentation in over 20 languages. English-speaking accompaniment is standard at hospitals with mature international departments.
For Josh, the treatment journey was personal. After his month and a half of treatment, he was eating normally again — soups, ice cream — and carrying the chocolate the staff had given him as a farewell gift.
Why China's doctors and hospitals are attracting international patients
It's not just the drugs. China's healthcare system has structural advantages that matter enormously when you're fighting cancer.
Surgical volume: At Peking University International Hospital, foreign patients now make up 50% of the international medical center's caseload. A thoracic surgeon in China performs 400–500 surgeries a year — some over 1,000. A comparable Western surgeon might do 100. That volume translates into skill and experience with rare complications.
Complex case expertise: In July 2026, the hospital's international center convened a four-specialty team (pediatrics, dermatology, ENT, plastic surgery) for a Bangladeshi child who had visited Singapore, Bangladesh, and India without a diagnosis. The team identified a rare congenital skin condition and built a one-stop treatment plan.
The price-quality equation: Hospital prices in China run roughly 3–10x the public medical insurance rate. Operative and surgical services run 8–10x; diagnostic tests run 2–5x. Even at these premium rates, the total cost is still a fraction of comparable care in the US or Europe. Some international hospitals reach 60% gross margins — and that profitability is driving rapid expansion. In the first quarter of 2026 alone, nine hospitals announced new international departments.
The bigger picture: China's medical tourism is booming
The numbers tell the story. According to China's National Health Commission, cross-border medical service revenue exceeded 80 billion RMB in the first three quarters of 2025, growing over 30% year on year. Key foreign hospitals treated 1.28 million international patients over the full year — up 73.6% from three years earlier, with patients from Europe and America doubling.
The fastest-growing categories: oncology treatment, cardiovascular surgery, and CAR-T cell immunotherapy — the treatments that save lives.
China's government is leaning in. In March 2026, nine government departments issued new policies to expand inbound health consumption, develop international medical tourism brands, and improve international medical service standards. At least 20 provinces and cities have launched international medical pilot programs.
Which hospitals to consider
For cancer treatment and advanced immunotherapy, these hospitals stand out:
- Shanghai Jiahui International Hospital — Shanghai's top private international hospital, serving 100,000+ foreign patients in 2025, 8 languages, strong oncology center, 24-hour diagnostics
- Peking University International Hospital — Beijing, foreign patients are 50% of international caseload, strong in complex multidisciplinary cases
- Fudan University-affiliated hospitals / Shanghai Cancer Center — top academic oncology centers
- Tongji University-affiliated East Hospital — home of Professor Zhou Caicun, key investigator for ivonescimab
When choosing, ask about: JCI accreditation, English-speaking staff, international insurance direct billing, multilingual medical records, and whether the specific drug or therapy you need is available.
The bottom line
For patients with advanced cancer who have run out of options, China is no longer just a cheaper alternative — it's sometimes the only place with the treatment. The world's first solid-tumor CAR-T, the China-only approval of ivonescimab, the surgical volume, and the 48-hour diagnostic speed are not marketing claims. They are the reasons Josh flew 11 hours from New Zealand, and why Daniel's doctor-children booked him to Shanghai.
If you or a family member is facing advanced cancer, it's worth having a conversation about whether the treatment you need exists in China — and whether China's approach to diagnosis and treatment could give you options that don't exist anywhere else.